AGI-14100

AGI-14100 is a metabolically stable and orally available mIDH1 inhibitor (IC50=6 nM) . The pharmacochemical optimization of AGI-14100 is aimed at eliminating hPXR activation, resulting in the final drug candidate AG-120. AG-120 can be used in the study of cancers carrying IDH1 mutations. The discovery and development of AGI-14100 can be used for further studies of mutant isocitrate dehydrogenase 1 (mIDH1) inhibitors[1].

Product Specifications

CAS Number

[1448346-43-7]

UNSPSC

12352005

Target

Isocitrate Dehydrogenase (IDH)

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/agi-14100.html

Solubility

10 mM in DMSO

Smiles

O=C([C@@H](N1C2=NC=CC(C#N)=C2)CCC1=O)N([C@@H](C3=CC=CC=C3Cl)C(NC4CC(C4)(F)F)=O)C5=CC(F)=CC(F)=C5

Molecular Formula

C29H22ClF4N5O3

Molecular Weight

599.96

References & Citations

[1]Popovici-Muller J, et al. Discovery of AG-120 (Ivosidenib) : a first-in-class mutant IDH1 inhibitor for the treatment of IDH1 mutant cancers[J]. ACS medicinal chemistry letters, 2018, 9 (4) : 300-305.